BIOCON — NEW BIOSIMILAR APPROVAL WIN

Biocon Biologics has received Health Canada approval for Yesintek™ and Yesintek™ I.V. — its biosimilar version of Ustekinumab (reference drug: Stelara®). Why this matters Ustekinumab is used in auto-immune indications like Crohn’s, UC & psoriasis — a large global market Approval in a regulated market like Canada strengthens Biocon’s credibility and supports its global biosimilar scaling thesis Commercial launch timing and pricing strategy will decide financial impact — biosimilars are volume-driven but price-competitive Risks / Monitor Biosimilar launches face price erosion and payer negotiations Competition in Ustekinumab space is rising in the U.S./EU corridors Regulatory and patent timelines can delay monetisation in some markets